Ionis Pharmaceuticals
 | |
Formerly called | Isis Pharmaceuticals |
|---|---|
| Industry | Biotechnology |
| Headquarters | Carlsbad, United States |
| Products | Mipomersen, Alicaforsen |
| Website |
www |
Ionis Pharmaceuticals (NASDAQ: IONS), known as Isis Pharmeceuticals until December 2015,[1][2] is a publicly traded pharmaceutical company based in Carlsbad, California, United States. It has a single cholesterol-reducing drug in the market and several compounds in the drug pipeline including IONIS-HTTRx, the first intrathecally administered huntingtin-lowering drug for Huntington's disease;[3] and nusinersen (IONIS-SMNRx), an intrathecally administered antisense oligonucleotide drug for spinal muscular atrophy.
The company was founded in 1989 by Stanley Crooke, a former GlaxoSmithKline head of research, with a view to commercialize antisense therapy.[4]
References
- ↑ "Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals". www.prnewswire.com. PR Newswire/ Ionis Pharma. Retrieved 22 December 2015.
- ↑ Fikes, Bradley. "From Isis Pharma to Ionis". The San Diego Union-Tribune. San Diego Union Tribune. Retrieved 22 December 2015.
- ↑ "Landmark Huntington's trial starts - BBC News". BBC News. Retrieved 18 April 2016.
- ↑ Crooke, Stanley T (21 July 2011). "The Isis manifesto". Bioentrepreneur. doi:10.1038/bioe.2011.7.
External links
This article is issued from Wikipedia - version of the 5/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.